Nomura Asset Management Co. Ltd. Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Nomura Asset Management Co. Ltd. grew its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,004 shares of the biopharmaceutical company's stock after purchasing an additional 3,698 shares during the period. Nomura Asset Management Co. Ltd. owned about 0.08% of Regeneron Pharmaceuticals worth $90,411,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. SteelPeak Wealth LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 173.0% during the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company's stock worth $1,148,000 after acquiring an additional 692 shares during the period. Mizuho Securities USA LLC lifted its stake in Regeneron Pharmaceuticals by 625.5% during the third quarter. Mizuho Securities USA LLC now owns 59,341 shares of the biopharmaceutical company's stock worth $62,382,000 after purchasing an additional 51,162 shares during the last quarter. Tri Locum Partners LP boosted its holdings in shares of Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company's stock valued at $18,410,000 after purchasing an additional 8,949 shares in the last quarter. Simplify Asset Management Inc. increased its stake in shares of Regeneron Pharmaceuticals by 50.8% in the 3rd quarter. Simplify Asset Management Inc. now owns 9,591 shares of the biopharmaceutical company's stock valued at $10,082,000 after purchasing an additional 3,231 shares during the last quarter. Finally, Catalytic Wealth RIA LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $1,334,000. Institutional investors and hedge funds own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the company. Wolfe Research started coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. BMO Capital Markets cut their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Finally, Morgan Stanley cut their target price on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating on the stock in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $10.10 during trading hours on Monday, reaching $778.00. 813,685 shares of the company were exchanged, compared to its average volume of 798,371. The stock has a market capitalization of $85.49 billion, a P/E ratio of 19.25, a P/E/G ratio of 3.00 and a beta of 0.08. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1 year low of $735.95 and a 1 year high of $1,211.20. The business's 50 day simple moving average is $876.85 and its 200-day simple moving average is $1,011.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.